Multiple Myeloma Update

Authors

  • Angel Justiz Vaillant Department of Para-clinical Sciences, Pathology and Microbiology Unit, Faculty of Medical Sciences, The University of the West Indies, St. Augustine, Trinidad and Tobago.
  • Camille Elliott Department of Para-clinical Sciences, Pathology and Microbiology Unit, Faculty of Medical Sciences, The University of the West Indies, St. Augustine, Trinidad and Tobago.
Abstract:

This literature review presents the most recent developments in the management of multiple myeloma, which is characterized by the presence of abnormal plasma cells (myeloma cells) that accumulate into the bone marrow. Aspects related to pathophysiology, clinical manifestations, laboratory, study and treatment are described. These pieces of information  are necessary to accomplish a better management of the disease, and a reduction in economic burden and incidence of multiple myeloma.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Treatment of Multiple Myeloma

Les traitements classiques de myelome multiple et les schemas differents proposes ont ete mis en revue.  La poly chimiotherapie de la maladie avec une com-binaison de cyclophosphamide, B.C.N.U. Alkeran, Perdnisone et Vincristine a donnee une meilleur Resultat ceci surtout dans les formes graves et rapidement progressive de la maladie. D'autres sehemas therapeutiques sont en cours. 

full text

Multiple Myeloma Presenting as Respiratory Stridor

Extramedullary plasmacytoma occurs in 18% of patients with multiple myeloma. Laryngeal involvement in multiple myeloma is rare, and only a few cases have been reported. We present a case of a 44-year-old women with multiple myeloma who presented with stridor due to a mass involving the larynx which was initially proven to be plasmacytoma on biopsy. She had evidence of multiple myeloma of IgA la...

full text

Update on the initial therapy of multiple myeloma.

Advances in myeloma biology and the identification of new anti-myeloma agents have resulted in improved management of younger, transplant-eligible, and older patients. The first novel agents-thalidomide, bortezomib, and lenalidomide-have been integrated into induction therapy before autologous stem cell transplant (ASCT) as well as into first-line therapy in elderly individuals; phase III trial...

full text

Multiple myeloma: an update on biology and treatment.

Recently, several advances have been made in understanding the pathogenesis of multiple myeloma. Increasing evidence favours a pre-switched, but somatically mutated B-cell as myeloma stem cell to give rise to the malignant clone. Deletions of the p53-gene, partial or total loss of chromosome 13 and rearrangements of band 14q32 and 11q13 are frequently found in multiple myeloma, and were shown t...

full text

hematuria in multiple myeloma

. frequent macroscopic hematuria in multiple myeloma is quite rare and exceptional and no report has been found in the literature. we have presented a case of multiple myeloma who developed frequent episodes of gross hematuria during her long lasting but slowly progressing course of the disease

full text

MULTIPLE MYELOMA Myeloma bone disease

Bone destruction is a hallmark of multiple myeloma, and recent studies demonstrated a strong interdependence between tumor progression and bone resorption. Increased bone resorption as a major characteristic of multiple myeloma is caused by osteoclast activation and osteoblast inhibition (uncoupling). Myeloma cells alter the local regulation of bone metabolism by increasing the receptor activat...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 4  issue None

pages  0- 0

publication date 2018-08

{@ msg @}

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023